Latest news and press releases about Silence Therapeutics plc (SLN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver.
Price
| Price | $12.50 |
| Market Cap | $590M |
| Exchange | NASDAQ |
| Country | GB |
Valuation Ratios
| Price / Book | 5.00 |
| EV / EBITDA | -9.01 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -106.94% |
| Return on Invested Capital | -71.25% |
| Return on Assets | -56.34% |
| Gross Margin | 51.00% |
| Operating Margin | -10880.25% |
| Net Margin | -9759.23% |
Related companies: ACIU · ALDX · AMRN · ANRO · CAPR · CTNM · KYTX
Explore sector: Healthcare · Biotechnology
More sections of SLN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks